Improving cancer immunotherapy with SMAC mimetics
Enhancing the efficacy of immunotherapy by optimal use of SMAC mimetics
['FUNDING_OTHER'] · UNIVERSITY OF TX MD ANDERSON CAN CTR · NIH-10986072
This study is looking at how a new type of treatment called SMAC mimetics can make existing cancer immunotherapies, especially those that block a protein called PD-1, work better for patients with cancer.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF TX MD ANDERSON CAN CTR (nih funded) |
| Locations | 1 site (HOUSTON, UNITED STATES) |
| Trial ID | NIH-10986072 on ClinicalTrials.gov |
What this research studies
This research investigates how SMAC mimetics can enhance the effectiveness of existing cancer immunotherapy treatments, particularly those that block the programmed cell death protein 1 (PD-1). The approach involves understanding the specific conditions under which SMAC mimetics work best when combined with PD-1 blockade therapies. By utilizing advanced techniques such as machine learning and single-cell technologies, the research aims to develop personalized treatment strategies that could lead to better outcomes for cancer patients. The project is supported by a team of experts in cancer immunology and computational biology, ensuring a comprehensive approach to the problem.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients undergoing treatment for cancers that are currently treated with PD-1 blockade therapies.
Not a fit: Patients who are not receiving PD-1 blockade therapies or those with cancers not responsive to immunotherapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective cancer treatments that improve patient survival rates and quality of life.
How similar studies have performed: Previous research has shown promising results in enhancing immunotherapy efficacy through combination therapies, indicating that this approach has potential for success.
Where this research is happening
HOUSTON, UNITED STATES
- UNIVERSITY OF TX MD ANDERSON CAN CTR — HOUSTON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: GU, SHENGQING — UNIVERSITY OF TX MD ANDERSON CAN CTR
- Study coordinator: GU, SHENGQING
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: anti-cancer immunotherapy, anti-cancer therapy